疑似ACS患者高敏肌钙蛋白检测转换的临床决策与结局:中断时间序列研究
转换后心肌损伤识别比例从21%升至38%,住院风险增加(OR 2.24),系列检测增加6倍,但1年内心梗、心衰或心血管死亡无改善。
要点
- 从高敏肌钙蛋白I转换为T检测后,心肌损伤识别比例从21%升至38%。
- 转换后住院风险显著增加(OR 2.24,95%CI 1.81-2.77,P<.001)。
- 系列检测增加6倍(OR 6.03),但1年心血管结局无改善(OR 0.83,P=.49)。
核心结论
- 从高敏肌钙蛋白I转换为高敏肌钙蛋白T检测与心肌损伤识别增加、系列检测增加和住院增加相关,但1年心血管结局无改善证据。
研究设计与样本
- 前瞻性、多中心、中断时间序列研究,在3个急性护理中心进行。
主要发现
- 住院风险增加(OR 2.24;95%CI 1.81-2.77;P<.001)。
- 系列检测增加6倍(OR 6.03;95%CI 4.85-7.49;P<.001)。
- 1年后续心肌梗死、心力衰竭或心血管死亡在转换前后相当(OR 0.83;95%CI 0.48-1.41;P=.49)。
临床怎么用
- 临床医生应意识到高敏肌钙蛋白T检测可能增加心肌损伤识别和住院,需结合临床综合判断。
- 系列检测增加可能带来额外医疗负担,应优化检测策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: High-sensitivity cardiac troponin T and I assays are considered equivalent for the diagnosis of myocardial infarction. However, the impact of transitioning from an assay measuring cardiac troponin I to one measuring cardiac troponin T on patient care and clinical outcomes is unknown. OBJECTIVE: To evaluate the impact of transitioning from a high-sensitivity assay measuring cardiac troponin I to one measuring cardiac troponin T on the care and outcomes of consecutive patients with suspected acute coronary syndrome. DESIGN, SETTING, AND PARTICIPANTS: This was a prospective, multicenter, interrupted time-series study conducted at 3 acute care centers. Consecutive patients presenting with suspected acute coronary syndrome to an acute care hospital were identified between October 2020 and October 2022. INTERVENTIONS: All sites changed from an assay measuring cardiac troponin I to one measuring cardiac troponin T in October 2021. MAIN OUTCOMES AND MEASURES: The primary outcome was hospital admission. RESULTS: Among 25 849 patients, 13 146 (median [IQR] age, 60 [47-73] years; 6961 male [53%]) and 12 703 (median [IQR] age, 60 [47-73] years; 6825 male [54%]) presented before and after the transition to cardiac troponin T, respectively. The proportion of patients with myocardial injury increased from 21% (2800 of 13 146 patients) to 38% (4781 of 12 703 patients), and patients were more likely to be admitted to the hospital after the transition (odds ratio [OR], 2.24; 95% CI, 1.81-2.77; both P < .001). A 6-fold increase in serial testing was observed in patients undergoing a measure of cardiac troponin T compared with cardiac troponin I (OR, 6.03; 95% CI, 4.85-7.49; P < .001). Subsequent myocardial infarction, heart failure, or cardiovascular death at 1 year was comparable before and after the transition (OR, 0.83; 95% CI, 0.48-1.41; P = .49). CONCLUSIONS AND RELEVANCE: The transition from a high-sensitivity assay measuring cardiac troponin I to one measuring cardiac troponin T was associated with increased identification of myocardial injury, serial troponin measurements, and hospital admissions without evidence of improved cardiovascular outcomes at 1 year. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05748691.
引用
- Boeddinghaus, Li, Bularga, et al. Clinical Decisions and Outcomes After Switching High-Sensitivity Cardiac Troponin Assays in Suspected ACS: An Interrupted Time-Series Study. JAMA Cardiol. 2026. PMID: 41405901. doi:10.1001/jamacardio.2025.4661
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。